Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
John Wiley Sons Cl A ( (WLY) ) just unveiled an announcement.
On June 17, 2025, Wiley reported its fiscal 2025 results, highlighting significant achievements such as exceeding adjusted EPS guidance, expanding profit margins, and reaffirming fiscal 2026 growth targets. The company realized $40 million in AI licensing revenue, compared to $23 million in the previous year, and increased share repurchases by 34%, raising dividends for the 31st consecutive year. Wiley’s fiscal year saw a 3% increase in adjusted revenue, a 29% rise in adjusted operating income, and a 10% growth in free cash flow, driven by strong performance in its Research and Learning segments. The company also completed divestitures, receiving $120 million in cash proceeds, and continued its focus on AI licensing and partnerships, science analytics, and knowledge services.
Spark’s Take on WLY Stock
According to Spark, TipRanks’ AI Analyst, WLY is a Neutral.
The overall score reflects significant financial challenges and technical weakness. Positive elements from the earnings call, such as research and AI licensing growth, and strategic board appointment are offset by high leverage, negative cash flow, and a high P/E ratio suggesting overvaluation.
To see Spark’s full report on WLY stock, click here.
More about John Wiley Sons Cl A
Wiley (NYSE: WLY) is one of the world’s largest publishers and a trusted leader in research and learning, offering industry-leading content, services, platforms, and knowledge networks to researchers, students, instructors, professionals, institutions, and corporations.
Average Trading Volume: 410,124
Technical Sentiment Signal: Sell
Current Market Cap: $2B
For detailed information about WLY stock, go to TipRanks’ Stock Analysis page.